BioSpace News Archive

IntelGenx Corp. announced that it is executing on a plan focussed on near-term revenue generation.

Merus N.V. (Nasdaq: MRUS) today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference 2023 on Wednesday, June 7, 2023 at 11:30 a.m. ET.

Pathalys Pharma, Inc. today announced that the first patient has been enrolled in the PATH (PTH Attenuation Trial in Hemodialysis) clinical program, consisting of two identical phase 3 trials, to assess upacicalcet for the treatment of secondary hyperparathyroidism (SHPT) in end-stage kidney disease (ESKD) patients on hemodialysis.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced an oral presentation on the company’s recently completed Phase 1b/2a SWARM-P.a. clinical trial at the 6th World Conference on Targeting Phage Therapy.

Mission Bio, Inc. today announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications.

Precigen, Inc. today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase 2 study of the first-in-class PRGN-2009 Off-the-Shelf (OTS) AdenoVerse™ immunotherapy in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer.

Charles River Laboratories International, Inc. and Wheeler Bio, Inc., a contract development and manufacturing organization, announced an agreement to implement RightSourceSM at Wheeler Bio’s current good manufacturing practice biologics manufacturing facility in Oklahoma City, OK.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new analyses from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate show a multi-faceted impact when treating adults living with chronic gout refractory to oral therapy, or uncontrolled gout.

Cartography Biosciences today announced the appointments of Tara Arvedson, Ph.D., and Janine Schuurman, Ph.D., to its Scientific Advisory Board.

Attendees will be the first to see outcomes from the complete patient series within MIRA’s Investigational Device Exemption clinical study.